Background: There is a growing body of evidence on the risks and benefits of influenza vaccination in 2
1

Methodological quality of systematic reviews on influenza vaccination
Introduction 28
When considering the best available evidence regarding vaccination, results of randomized 29 controlled trials (RCTs), systematic reviews, and meta-analyses on vaccine efficacy and safety are 30 commonly used to guide immunization policy decisions. For influenza vaccines, however, the unique 31 epidemiological features of influenza viruses with seasonal variations potentially leading to a 32 mismatch between vaccine and circulating strains complicate the interpretation of single studies 33
reporting data from only one or two seasons and increase the importance of summarized evidence in 34 terms of systematic reviews. In addition, since most influenza vaccines are licensed only based on 35 RCTs demonstrating immunogenicity and not efficacy in preventing clinical outcomes, there is a need 36 to consider high-quality observational studies assessing vaccine effectiveness (1, 2) . Finally, the 37 interpretation of efficacy and effectiveness studies is further complicated by the fact that there are 38 obvious differences in influenza vaccine efficacy/effectiveness by vaccine type and age-group (3) . 39 Therefore, systematic reviews of high quality that address the safety and protective effects of 40 influenza vaccination in various vaccination target groups are of particular importance. 41 Systematic reviews and meta-analyses are used to synthesize results of primary 42 investigations on a specific subject and have been advocated as a way to keep up to date with 43 current medical literature (4) . Using a rigorous methodology with a clearly formulated research 44 question and a comprehensive search strategy, systematic reviews should provide reproducible 45 results and include all potentially relevant studies, thereby limiting bias and random errors (5, 6 
Results
115
The systematic literature review led to the identification of 564 publications. After exclusion of 116 irrelevant records or studies which did not fulfill the inclusion criteria (see Appendix 2 for the list of  117 excluded studies), a total of 46 systematic reviews were found to be eligible (Figure 1) . 118
Review topics covered by the included systematic reviews are shown in Table 1 . Two updates of 119 systematic reviews were published after the time of the literature search and were not included in 120 this article (63, 64) . 121 Table 2 summarizes major characteristics of the included systematic reviews. About 50% 122 were published in 2010 or later in a specialized journal. A quarter of them were Cochrane reviews, 123 less than 20% of the reviews were funded by pharmaceutical companies and about 50% included 124 observational studies. Observational studies were less likely to be included in Cochrane than in non-125 Cochrane reviews (3/11 (27.3%) vs. 22/35 (62.9%)) and in reviews funded by pharmaceutical industry 126
(1/6 (16.7%) vs. 24/40 (60.0%)), respectively; however, these differences were not statistically 127 significant (p=0.08 for both). 128
On average, methodological quality of the systematic reviews was high, indicated by a 129 median AMSTAR summary score of 8, but variability was large (range: 0-11). 130
We then analyzed whether methodological quality of reviews differed according to review 131 topic (i.e. vaccination target group). As shown in Figure 2 , AMSTAR summary scores did not differ 132 largely between review topics, except for reviews on vaccination in the general population, which 133 tended to be of lower quality than those on other topics. However, differences in AMSTAR scores 134 between topics were not statistically significant. Therefore, we decided to perform all subsequent 135 analyses on the entire set of reviews as one single study base. 136
In the next step, we analyzed which characteristics of the reviews had an impact on 137 methodological quality. Table 3 shows AMSTAR summary scores according to the presence or 138 absence of major study characteristics (bivariate analyses). Cochrane reviews had a significantly 139 higher methodological quality than non-Cochrane reviews (p=0.001). Furthermore, reviews published 140 9 in specialized journals were of slightly but significantly lower quality than those which came from 141 generalized journals (p=0.03). None of the other factors had an impact on methodological quality. 142
In order to analyze the impact of shortened "journal article versions" of Cochrane reviews, 143
we performed a sensitivity analysis excluding the full-length Cochrane versions of the respective 144 reviews from the database, i.e. references (23, 31, 38, 39) and repeated the main analysis. In this 145 restricted data set, Cochrane reviews still had significantly higher AMSTAR summary scores (median: 146 9; range: 8-10) than non-Cochrane reviews (median: 7; range: 0-10; p=0.004), whereas the score did 147 not differ regarding all other review characteristics (publication date; specialized journal; impact 148 factor; no. of included studies; inclusion of observational studies; funding). 149
To further determine the extent by which these factors influenced the methodological quality of the 150 systematic reviews on influenza vaccination, we performed multivariable linear regression analysis 151 (Table 4) . According to R², 27% of the variability of the methodological quality of the systematic 152 reviews was explained by the seven factors in the model. However, in this model, only Cochrane 153 review status (yes/no) had a significant influence on AMSTAR summary score. This result was 154 confirmed when stepwise regression was performed to eliminate non-significant covariates: Again, 155
Cochrane review status was the only covariate which influenced AMSTAR summary score (p=0.001; 156 R²=0.21). Therefore, we aimed to analyze whether these differences in review quality are caused by 157 particular methodological features of Cochrane reviews. Accordingly, we compared the proportion of 158 reviews which fulfilled the different AMSTAR domains (i.e., domains were answered by "yes") 159 between Cochrane and non-Cochrane reviews (Figure 3) . Cochrane reviews had significantly higher 160 methodological quality (i.e., domains were more often answered by "yes") regarding domains No. In view of an expanding body of evidence related to the safety and protective effects of influenza 167 vaccination and the complexity of the topic, we aimed to investigate the methodological quality of 168 the available systematic reviews. To the best of our knowledge, this is the first study which used the 169 AMSTAR tool to assess the quality of systematic reviews in the field of immunization in general and 170 on influenza vaccination in particular. We found that on average systematic reviews on influenza 171 vaccination had a high quality, with reviews conducted by the Cochrane collaboration being of higher 172 quality than others. Although AMSTAR score was highest for reviews focusing on influenza vaccines 173 in healthcare workers, lung diseases and malignancies with a median score of 9, and lowest in 174 reviews dealing with the general population (median of 5), this difference was not statistically 175 significant. The fact, that the overall quality of published systematic reviews on influenza vaccination 176 is generally high is important for clinicians and health policy decision makers when the best available 177 evidence is considered to guide immunization policy decisions. However, since some reviews 178 revealed obvious flaws leading to low AMSTAR scores and one review even received an AMSTAR 179 score of zero, critical appraisal of the methodological quality remains important in the field of 180 systematic reviews on influenza vaccination. 181
So far, only one study has assessed the methodological quality of systematic reviews and 182 meta-analyses on vaccines. Using the Oxman-Guyatt tool, Vito et al. systematically investigated the 183 methodological quality of systematic reviews of vaccines in general and found it to be not 184 satisfactory (65) . In their paper, they identified major flaws in comprehensiveness of literature 185 search, selection of studies for inclusion, quality assessment of included studies, and analysis of 186 publication bias. Methodological quality of the systematic reviews was found to depend on type of 187 included studies (RCTs vs. observational studies), year of publication, financial support (non-profit vs. reviews of the Cochrane Skin group were methodologically more rigorous than other systematic 208 reviews in dermatology (68) . 209
Interestingly, in our study we were unable to identify differences in methodological quality 210 when comparing systematic reviews that were funded by pharmaceutical companies to those 211 without such funding. In contrast, Jørgensen et al. found that industry supported reviews had more 212 favorable conclusions and were less likely to report methodological limitations of included trials than 213 corresponding Cochrane reviews of the same drugs (69) . It is important to understand in this respect 214 that issues like drawing conclusions or highlighting limitations are not captured by tools like AMSTAR, 215 which are used to measure only the methodological quality of systematic reviews. Therefore, even if 216 pharmaceutical funding did not affect the methodological quality of influenza vaccination reviews,12 reporting of potential conflicts of interest and funding sources remains important when the results of 218 systematic reviews are interpreted and conclusions are drawn. 219
It is furthermore important to note that according to our study, none of the included non-220 Cochrane reviews and less than 20% of Cochrane reviews declared conflict of interest of all included 221 studies (AMSTAR domain 11). This is corroborated by Roseman et al. who investigated to which 222 extend systematic reviews of drug treatments published in the Cochrane Database of Systematic 223
Reviews reported conflicts of interest from included trials and the review itself. Only 30% of reviews 224 reported information on funding source of included trials and only 20% reported information on trial 225 funding for all included trials (70) . To this end, there is a need for improvement in both, Cochrane 226 and non-Cochrane reviews in reporting potential conflicts of interest for all included studies and the 227 review itself. 228
According to AMSTAR domain 10, publication bias was reported in only 36.4% of Cochrane 229 and 40% of non-Cochrane reviews. Publication bias can occur when studies on the same research 230 question are more likely to be published when containing statistically significant or "hoped-for" 231 results (71) . Since undetected publication bias may lead to imprecise or misleading results of 232 systematic reviews, statistical approaches such as funnel plots and regression test proposed by Egger 233 and colleagues has been developed and should be used to detect publication bias (72) . However, 234 even if measures to identify publication bias have improved in recent years (73), the reporting rate 235 in reviews on influenza vaccines is still not satisfactory. It should be emphasised, that the purpose of 236
this paper was not to analyze or discuss results of included reviews and that even reviews of high 237 methodological quality should be interpreted with caution. For example, even "empty reviews" that 238 did not identify any study to be eligible can reach a high AMSTAR-score if performed thoroughly. And 239 for certain research questions a review based solely on RCTs might provide only limited evidence, 240 irrespective of its methodological quality. In such cases, inclusion of observational studies might 241 increase the overall value of the review, but this does not necessarly translate to a higher 242 methodological quality as indicated by a higher AMSTAR score. Thereby, AMSTAR score, as a 243 13 measure of methodological quality, does not provide information on the usefulness of the results of 244 the respective systematic review for the development of prevention policies. 245
It is possible, that differences in the average AMSTAR-scores may be partly explained by the 246 fact, that Cochrane authors could publish their articles in an online journal with unlimited space, 247 whereas non-Cochrane authors publish in other journals with limitation of word numbers. However, 248 the sensitivity analysis revealed, that the impact of unlimited space of Cochrane journals was small in 249 regard of the methodological quality. Moreover, since most AMSTAR-items (except item 5) could be 250 answered by a single sentence and almost all journals offer the opportunity to upload online 251 supplementary material as standard practice, these issues can be easily met also by authors of 252 standard journal articles. In general, methodological flaws in the conduct of systematic reviews could 253 be avoided by consulting references such as the Cochrane handbook before starting a systematic 254 review. 255
Our study has several strengths: It is based on a a systematic literature search strategy, 256 thereby ensuring comprehensiveness. Furthermore, the AMSTAR tool was applied to systematic 257 reviews on vaccination which covered a variety of vaccination target groups. However, our approach 258 was limited to English and German language papers and to those published after 1990, which were 259 chosen for the reason of practicability. 260
In summary, this methodological study shows that systematic reviews on influenza 261 vaccination had on average a high methodological quality but variability was large. Reviews 262 conducted by the Cochrane collaboration were of higher quality than others, whereas other factors 263 such as industry sponsorship, journal impact factor, and type of included studies did not significantly 264
influence the methodological quality of systematic reviews on this topic. Our findings support the 265 notion that a high methodological quality is the basic precondition of systematic reviews for 266 identifying the best available evidence regarding specific research questions. However, a high 267 methodological quality does not automatically reflect usefulness of the content of a review. To this 268 end, both methodological quality of a review and its content have to be considered when using 269 systematic reviews to guide immunization policy decisions. 270 Tables   Table 1: Topics of included systematic reviews on influenza vaccination Topic (vaccination target groups ) N (reviews)
General population 3
Healthy children 8
Healthy adults 3
Elderly persons 4
Health care workers 6.
Were the characteristics of the included studies provided?
7.
Was the scientific quality of the included studies assessed and documented?
8.
Was the scientific quality of the included studies used appropriately in formulating conclusion?
9.
Were the methods used to combine the findings of the studies appropriate?
10.
Was the likelihood of publication bias assessed?
11.
Were potential conflicts of interest declared? 
